Esperion Therapeutics
ESPR
ESPR was delisted on the 10th of July, 2026.
124 hedge funds and large institutions have $104M invested in Esperion Therapeutics in 2023 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 30 increasing their positions, 37 reducing their positions, and 61 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
78% more call options, than puts
Call options by funds: $2.51M | Put options by funds: $1.41M
12.65% less ownership
Funds ownership: 91.19% → 78.54% (-13%)
19% less repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 37
20% less capital invested
Capital invested by funds: $129M → $104M (-$25.5M)
24% less funds holding
Funds holding: 164 → 124 (-40)
62% less first-time investments, than exits
New positions opened: 23 | Existing positions closed: 61
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$7.7M |
| 2 |
TSC
Two Seas Capital
Rye,
New York
|
+$4.11M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$1.92M |
| 4 |
PIM
Platinum Investment Management
Sydney Australia 2000,
Australia
|
+$1.24M |
| 5 |
MAM
Monaco Asset Management
Monaco
|
+$771K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Balyasny Asset Management
Chicago,
Illinois
|
-$6.64M |
| 2 |
BlackRock
New York
|
-$4.91M |
| 3 |
State Street
Boston,
Massachusetts
|
-$2.24M |
| 4 |
GCM
Graham Capital Management
Rowayton,
Connecticut
|
-$1.64M |
| 5 |
RPAM
Rhenman & Partners Asset Management
Stockholm,
Sweden
|
-$1.5M |
ESPR Hedge Fund Activity: Q2 2023 in Review
124 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Esperion Therapeutics (ESPR) for Q2 2023, worth a combined $104M — down 20% from $129M a quarter earlier.
Sellers outnumbered buyers: 61 funds closed out of ESPR and 23 opened new positions — a net loss of 38 holders — while 37 trimmed existing stakes and 30 added.
The largest buyer was Armistice Capital, adding an estimated $7.7M. The largest seller was Balyasny Asset Management, cutting an estimated $6.64M.
- 124 institutional investors held Esperion Therapeutics (ESPR) as of Q2 2023, down from 164 in Q1 2023.
- Funds reported $104M of Esperion Therapeutics stock for Q2 2023, down 20% quarter-over-quarter.
- 23 funds opened new Esperion Therapeutics positions in Q2 2023 and 61 closed out, a net change of -38 holders.
- The largest Esperion Therapeutics buyer in Q2 2023 was Armistice Capital, an estimated $7.7M added.
- The largest Esperion Therapeutics seller in Q2 2023 was Balyasny Asset Management, an estimated $6.64M sold.
Based on aggregated 13F filings for Q2 2023.